Professor Jean-Claude Tardif (Montreal Heart Institute Research Centre and Professor of Medicine, University of Montreal, Montreal, Quebec, Canada) discusses the aims, rationale and recently released results of the COMMANDER-HF trial.
Filmed at ESC 2018, Munich.
View more content here.
Speaker Disclosure: Professor Jean-Claude Tardif has the following disclosures in relation to this video interview: grants from Amarin, AstraZeneca, DalCor, Esperion, Ionis, Pfizer, Sanofi and Servier. Honoraria from DalCor, Pfizer, Sanofi, Servier. Minor equity interest in DalCor.
1. Please describe the key aims of the COMMANDER-HF trial of rivaroxaban? (0:08)
2. What do we already know about the efficacy and safety of rivaroxaban and what was the rationale behind the COMMANDER-HF trial? (1:05)
3. Which patient groups were eligible for inclusion in the COMMANDER-HF trial? (2:28)
4. What separates the COMMANDER-HF trial from previous trials of oral anticoagulants in heart failure? (3:01)
5. What were the lessons from the COMMANDER-HF trial? (3:39)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via open-access content in multimedia formats.
Share this Video
Related Videos In Heart Failure
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Hugh Calkins, AF Symposium 2021: Atrial Fibrillation and HFrEF and HFpEF
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction. Questions: What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13) What is the impact of AF on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!